JP2023513704A5 - - Google Patents
Info
- Publication number
- JP2023513704A5 JP2023513704A5 JP2022548599A JP2022548599A JP2023513704A5 JP 2023513704 A5 JP2023513704 A5 JP 2023513704A5 JP 2022548599 A JP2022548599 A JP 2022548599A JP 2022548599 A JP2022548599 A JP 2022548599A JP 2023513704 A5 JP2023513704 A5 JP 2023513704A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- erdafitinib
- patient
- fgfr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062975547P | 2020-02-12 | 2020-02-12 | |
| US62/975,547 | 2020-02-12 | ||
| US202063018914P | 2020-05-01 | 2020-05-01 | |
| US63/018,914 | 2020-05-01 | ||
| US202063118475P | 2020-11-25 | 2020-11-25 | |
| US63/118,475 | 2020-11-25 | ||
| PCT/EP2021/053385 WO2021160764A1 (en) | 2020-02-12 | 2021-02-11 | Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023513704A JP2023513704A (ja) | 2023-04-03 |
| JP2023513704A5 true JP2023513704A5 (https=) | 2024-02-21 |
Family
ID=74666675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548599A Withdrawn JP2023513704A (ja) | 2020-02-12 | 2021-02-11 | 高リスク筋層非浸潤性膀胱癌を治療するためのｆｇｆｒチロシンキナーゼ阻害剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230110113A1 (https=) |
| EP (1) | EP4103185A1 (https=) |
| JP (1) | JP2023513704A (https=) |
| KR (1) | KR20220140781A (https=) |
| CN (1) | CN115103678A (https=) |
| AU (1) | AU2021220285A1 (https=) |
| BR (1) | BR112022015827A2 (https=) |
| CA (1) | CA3162962A1 (https=) |
| IL (1) | IL295514A (https=) |
| JO (1) | JOP20220182A1 (https=) |
| MX (1) | MX2022009905A (https=) |
| PH (1) | PH12022552093A1 (https=) |
| TW (1) | TW202143970A (https=) |
| WO (1) | WO2021160764A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312063A (en) * | 2021-10-12 | 2024-06-01 | Taris Biomedical Llc | Ardafitinib formulations and systems for intravesical administration |
| KR20240145513A (ko) * | 2022-02-18 | 2024-10-07 | 타리스 바이오메디컬 엘엘씨 | 에르다피티닙 제형 및 방광내 투여를 위한 삼투성 시스템 |
| KR20250143348A (ko) * | 2023-02-13 | 2025-10-01 | 타리스 바이오메디컬 엘엘씨 | 방광암 치료에 사용하기 위한 방광내 투여용 에르다피티닙 |
| EP4665341A1 (en) * | 2023-02-13 | 2025-12-24 | Janssen Pharmaceutica NV | Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
| CN120731077A (zh) * | 2023-02-17 | 2025-09-30 | 塔里斯生物医药公司 | 膀胱内施用厄达替尼以用于治疗膀胱癌 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| EP0951541B1 (en) | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| BRPI0611375A2 (pt) | 2005-05-23 | 2010-08-31 | Novartis Ag | formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| KR102470456B1 (ko) * | 2014-09-26 | 2022-11-23 | 얀센 파마슈티카 엔.브이. | Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용 |
| TWI719960B (zh) * | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| HUE062453T2 (hu) * | 2017-02-06 | 2023-11-28 | Janssen Pharmaceutica Nv | Rákbetegség kezelése |
| TWI798199B (zh) * | 2017-02-06 | 2023-04-11 | 比利時商健生藥品公司 | 癌症治療 |
-
2021
- 2021-02-11 CN CN202180014162.9A patent/CN115103678A/zh active Pending
- 2021-02-11 IL IL295514A patent/IL295514A/en unknown
- 2021-02-11 AU AU2021220285A patent/AU2021220285A1/en active Pending
- 2021-02-11 KR KR1020227031209A patent/KR20220140781A/ko active Pending
- 2021-02-11 US US17/904,139 patent/US20230110113A1/en active Pending
- 2021-02-11 WO PCT/EP2021/053385 patent/WO2021160764A1/en not_active Ceased
- 2021-02-11 MX MX2022009905A patent/MX2022009905A/es unknown
- 2021-02-11 PH PH1/2022/552093A patent/PH12022552093A1/en unknown
- 2021-02-11 EP EP21706187.8A patent/EP4103185A1/en active Pending
- 2021-02-11 JP JP2022548599A patent/JP2023513704A/ja not_active Withdrawn
- 2021-02-11 BR BR112022015827A patent/BR112022015827A2/pt unknown
- 2021-02-11 CA CA3162962A patent/CA3162962A1/en active Pending
- 2021-02-17 TW TW110105372A patent/TW202143970A/zh unknown
-
2022
- 2022-08-09 JO JOP/2022/0182A patent/JOP20220182A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023513704A5 (https=) | ||
| US20240299388A1 (en) | Erk1/2 and shp2 inhibitors combination therapy | |
| Stadler et al. | A phase II study of depsipeptide in refractory metastatic renal cell cancer | |
| Goldberg et al. | Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. | |
| US9486445B2 (en) | Combination therapy for proliferative disorders | |
| AU2016244279B2 (en) | Method of adjuvant cancer treatment | |
| EA037152B1 (ru) | Способ лечения рака | |
| WO2017201156A1 (en) | Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab | |
| AU2018234903B2 (en) | Combination therapies for the treatment of breast cancer | |
| JP2023516951A (ja) | アルペリシブおよび６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸を含む組合せ物 | |
| JP2022534118A5 (https=) | ||
| HUP0204139A2 (en) | Use of n-[6-methoxi-5-(2-methoxiphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2phenyl-etienesulfonamide for producing pharmaceutical composition using for reducing pain in an endothelin-induced disease | |
| TW202034921A (zh) | 癌症療法 | |
| EP1973542A2 (en) | Treatment of cachexia with statins | |
| JP2022500485A (ja) | グラピプラント単位剤形 | |
| JP2021525263A (ja) | 処置 | |
| KR20230043598A (ko) | 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염 및 항바이러스제를 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물 | |
| TW200412971A (en) | Therapeutic treatment | |
| KR101741281B1 (ko) | 건선 치료를 위한 ａ3 아데노신 수용체 작동약 (ｉｂ-ｍｅｃａ/ｃｆ-101)을 포함하는 제약학적 조성물 | |
| WO2020248240A1 (zh) | 痘苗病毒致炎兔皮提取物治疗癌症的用途 | |
| JP2025156297A (ja) | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 | |
| TW202332451A (zh) | 手部溼疹之治療 | |
| D'Arcangelo et al. | P2. 01-15 phase II single arm study of CABozantinib in non-small cell lung cancer patients with MET deregulation (CABinMET) | |
| JP2002523363A5 (https=) | ||
| George et al. | 4517 POSTER Sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) |